Detalhe da pesquisa
1.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
N Engl J Med
; 390(12): 1080-1091, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507751
2.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263519
3.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826360
4.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166679
5.
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
N Engl J Med
; 378(5): 439-448, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29385370
6.
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. Reply.
N Engl J Med
; 381(7): 687, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31412193
7.
A combined treatment of hydration and dynamical effects for the modeling of host-guest binding thermodynamics: the SAMPL5 blinded challenge.
J Comput Aided Mol Des
; 31(1): 29-44, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27696239
8.
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Lancet Oncol
; 16(7): 816-29, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26092818
9.
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 15(6): 580-91, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24742739
10.
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Cancer
; 119(10): 1908-15, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23504821
11.
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
Breast Cancer Res Treat
; 141(3): 437-46, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24101324
12.
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer.
Ther Adv Med Oncol
; 15: 17588359231178125, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37275963
13.
Erratum to: A combined treatment of hydration and dynamical effects for the modeling of host-guest binding thermodynamics: the SAMPL5 blinded challenge.
J Comput Aided Mol Des
; 31(1): 45, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27815770
14.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
J Clin Oncol
; 39(13): 1458-1467, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769862
15.
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
JCO Precis Oncol
; 52021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34504990
16.
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Curr Hematol Malig Rep
; 14(1): 47-55, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30666506
17.
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
JAMA Oncol
; 4(10): 1367-1374, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29862411
18.
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Clin Cancer Res
; 24(24): 6175-6184, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190371
19.
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
J Clin Oncol
; 36(24): 2465-2472, 2018 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860922
20.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
J Clin Oncol
; 34(18): 2115-24, 2016 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091708